Cardiol Therapeutics Inc.

We are pleased to announce today our year-end 2024 update on operations. “Cardiol Therapeutics achieved significant milestones during 2024 which have supported advancing CardiolRx into the Phase III MAVERIC trial in recurrent pericarditis – a debilitating heart disease that remains underserved by available medicine,” said David Elsley, President and Chief Executive Officer of Cardiol Therapeutics. “We are very encouraged by the compelling Phase II data presented at the American Heart Association Scientific Sessions 2024, demonstrating that CardiolRx™ reduced pericarditis pain, inflammation, and episodes of recurrence in patients presenting with a high degree of disease burden. We were also pleased that our Phase II ARCHER trial surpassed expectations by completing patient enrollment ahead of schedule, positioning the Company to report topline data in Q2. With operations funded into the second half of 2026, we remain committed to advancing our late-stage clinical development pipeline in pericarditis and myocarditis, and to progressing the IND-enabling program to support the clinical development of CRD-38 for heart failure. We would like to express our sincere gratitude to our clinical collaborators and patients whose support has enabled our progress.” Please read the full press release: https://lnkd.in/ee2Hgadc #Cardiol #News #PressRelease

We are pleased to announce our participation to present at the TD Cowen 45th Annual Health Care Conference in Boston, MA, on March 5, 2025, at 11:10 a.m. EST. A live webcast of the presentation will be available under "Events & Presentations" in the Investors section of the Cardiol website. Please read the full press release: https://lnkd.in/eW8tjhpj #Cardiol #News #Conference #PressRelease

We are pleased to announce today the publication of research in the Journal of the American College of Cardiology: Basic to Translational Science, titled “Cannabidiol Prevents Heart Failure Dysfunction and Remodeling Through Preservation of Mitochondrial Function and Calcium Handling” (https://lnkd.in/ebwmkW6x). This research was conducted by scientists from Tecnológico de Monterrey who, together with researchers from the DeBakey Heart and Vascular Center in Houston, TX, are collaborating with Cardiol on the development of the Company’s proprietary subcutaneous formulation of cannabidiol, CRD-38, to treat heart failure with preserved ejection fraction. This common form of heart failure remains a leading cause of hospitalization worldwide and is associated with a five-year mortality that exceeds 75% in hospitalized patients. Please read the full press release: https://lnkd.in/eVHfrPiC #Cardiol #News #JACC #Research #PressRelease

We are pleased to announce today our participation at the upcoming the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025, at 4:00 p.m. EST. A live webcast of the presentation will be available under "Events & Presentations" in the Investors section of the Cardiol website. Please read the full press release: https://lnkd.in/eEnz_eA8 #Cardiol #News #Conference #PressRelease

We are pleased to announce today reported clinical results from its Phase II open-label MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis. The data showed that the marked improvements in both pericarditis pain and inflammation, previously reported at the 8-week primary endpoint, were maintained throughout the extension period of the 26-week study. The data were included in an oral presentation as part of the Laennec Clinician-Educator Award & Lecture at the American Heart Association Scientific Sessions 2024. “The data reported today show that patients enrolled in MAvERIC-Pilot, despite the severity of their disease, experienced clinically relevant and rapid reductions in both their pericarditis pain and C-reactive protein levels that were maintained throughout the study. In addition, results demonstrated a substantial reduction in pericarditis episodes per year as compared to the patients’ historical event rate prior to the study. Importantly, treatment was shown to be safe and well tolerated in a population who presented with significant disease burden,” said Dr. S. Allen Luis, Co-Director of the Pericardial Diseases Clinic and Associate Professor of Medicine in the Department of Cardiovascular Medicine at the Mayo Clinic. “I look forward to further investigation in the upcoming Phase II/III and Phase III clinical trials.” Please read the full press release: https://lnkd.in/gdX6M67N #Cardiol #ClinicalTrial #MAVERIC #Results #News #PressRelease

We are pleased to today announce plans to expand the MAVERIC clinical development program and advance CardiolRx™ into a late-stage clinical trial (MAVERIC-2) to evaluate the impact of CardiolRx™ in recurrent pericarditis patients following cessation of interleukin-1 (IL-1) blocker therapy. MAVERIC-2 is expected to be initiated during Q4 at major pericardial disease centres in the United States and Europe and to report results ahead of the Company’s planned pivotal Phase III study in recurrent pericarditis. “MAVERIC-2 provides an exciting opportunity to expand the market potential for CardiolRx through the execution of a cost-effective study and potentially provides a path for an accelerated regulatory approval timeline,” said David Elsley, President & CEO of Cardiol Therapeutics. “This important new study, designed in collaboration with an international panel of advisors comprised of experts in pericarditis, will also augment data from our planned Phase III MAVERIC-3 trial by exploring the potential for our lead oral drug candidate to assist the growing number of recurrent pericarditis patients who seek alternative options to chronic use of immunosuppressant biologics.” Please read the full press release: https://lnkd.in/eJgbYnpE #Cardiol #ClinicalTrial #MAVERIC #News #PressRelease

We are pleased to announce today that, further to its successfully completed public offering for gross proceeds of US$13.5 million, Canaccord Genuity has purchased an additional 1,265,625 Common Shares at the Offering Price pursuant to their exercise in full of the over-allotment option, for additional gross proceeds to the Company of $2,025,000 before deducting the underwriting commissions. After giving effect to the full exercise of the Over-Allotment Option, Cardiol sold 9,703,125 Common Shares under the Offering, for aggregate gross proceeds of US$15,525,000. The Company intends to use the net proceeds from the Offering to support the clinical development of CardiolRx for the treatment of recurrent pericarditis and for general and administrative expenses, working capital and other expenses. Please read the full press release: https://lnkd.in/eBy5vFJ5 #Cardiol #News #PressRelease

We are pleased to announce today the successful close of its previously announced public offering of Common Shares for gross proceeds of US$13.5 million. As previously stated, the Company intends to use the net proceeds from the Offering to support the clinical development of CardiolRx for the treatment of recurrent pericarditis and for general and administrative expenses, working capital and other expenses. Please read the full press release: https://lnkd.in/e46E3J7N #Cardiol #News #PressRelease

We are pleased to announce that we achieved the target patient enrollment in our phase II ARCHER trial investigating CardiolRx™ for acute myocarditis. "We are pleased to have achieved our target patient enrollment in the ARCHER trial, which reflects the commitment and dedication of our clinical collaborators and participating patients. Reaching this milestone is integral to enhancing our understanding of the therapeutic impact of CardiolRx™ in acute myocarditis, a debilitating and potentially life-threatening inflammatory heart disease that significantly impairs cardiac function and patient quality of life,” said Andrew Hamer, Cardiol Therapeutics’ Chief Medical Officer and Head of Research & Development. “With topline results expected early next year the data from the ARCHER trial is anticipated to offer key insights concerning the effects of CardiolRx™ on myocardial recovery. Furthermore, we anticipate these findings will complement the clinical data from our MAvERIC Phase II study in recurrent pericarditis, the full results of which will be presented in November at the American Heart Association Scientific Sessions 2024." Please read the full press release: https://lnkd.in/eVGEaw9V #Cardiol #News #ARCHER #PressRelease

Yesterday our President & CEO, David Elsley, joined Charles Payne on the Making Money show to discuss the rise in heart failure deaths among young adults and the latest advancements in the MAvERIC and ARCHER clinical programs. Watch the full discussion here: https://lnkd.in/erKudGZC